Search

Your search keyword '"Samalin L"' showing total 333 results
Start Over Author "Samalin L"
333 results on '"Samalin L"'

51. Is aggression a missed bipolar diagnostic feature in mixed depression?

Author

Verdolini, N., primary, Perugi, G., additional, Samalin, L., additional, Murru, A., additional, Angst, J., additional, Azorin, J.M., additional, Bowden, C.L., additional, Mosolov, S., additional, Young, A.H., additional, Barbuti, M., additional, Guiso, G., additional, Popovic, D., additional, Vieta, E., additional, and Pacchiarotti, I., additional

Published
2017
Full Text
View/download PDF

53. The aggressor at the mirror: Psychiatric correlates of deliberate self-harm in male prison inmates

Author

Verdolini, N., primary, Murru, A., additional, Attademo, L., additional, Garinella, R., additional, Pacchiarotti, I., additional, Bonnin, C. del Mar, additional, Samalin, L., additional, Pauselli, L., additional, Piselli, M., additional, Tamantini, A., additional, Quartesan, R., additional, Carvalho, A.F., additional, Vieta, E., additional, and Tortorella, A., additional

Published
2017
Full Text
View/download PDF

54. Determinants of Functioning in Euthymic Patients with Bipolar Disorder: A Structural Equation Modelling Approach

Author

Samalin, L., primary, Boyer, L., additional, Murru, A., additional, Pacchiarotti, I., additional, Reinares, M., additional, Bonnin, C.M., additional, Torrent, C., additional, Norma, V., additional, Corinna, P., additional, de Chazeron, I., additional, Boucekine, M., additional, Geoffroy, P.A., additional, Bellivier, F., additional, Llorca, P.M., additional, and Vieta, E., additional

Published
2017
Full Text
View/download PDF

56. Recommandations Formalisées d’Experts de l’Association Française de Psychiatrie Biologique et Neuropsychopharmacologie sur le dépistage et prise en charge du trouble bipolaire : mise à jour 2014

Author

de Chazeron, I., Pereira, B., Chéreau-Boudet, I., Brousse, G., Misdrahi, D., Fénelon, G., Tronche, A.-M., Schwan, R., Lancon, C., Marques, A., Debilly, B., Durif, F., Samalin, L., Guillaume, S., Courtet, P., Abbar, M., Lancrenon, S., Schreiner, A, Bergmans, P, Cherubin, A, Keim, A, Llorca, P.M., Cosar, A, Petralia, A., Corrivetti, P, Hargarter, A, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Biostatistiques, Inferential, CHU Clermont-Ferrand-Université d'Auvergne - Clermont-Ferrand I (UdA), Fondation FondaMental [Créteil], Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CHU Clermont-Ferrand, Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Centre Hospitalier Sainte Anne [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de psychiatrie A1, centre hospitalo-universitaire de Nîmes, 30900 Nîmes, France., Sylia Stat Lancrenon S.A.S., ENEA C.R. Frascati, Via E. Fermi, 45, 00044 Frascati, Roma, Italy, and affiliation inconnue

Subjects
[SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SCCO.NEUR]Cognitive science/Neuroscience, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2015

57. Recommandations Formalisées d’Experts de l’Association Française de Psychiatrie Biologique et Neuropsychopharmacologie sur le dépistage et prise en charge du trouble bipolaire : mise à jour 2014

Author

Samalin, L., Guillaume, S., Courtet, P., Abbar, M., Lancrenon, S., Llorca, P-M, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Centre Hospitalier Sainte Anne [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Sylia Stat Lancrenon S.A.S., and Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)

Subjects
Adult, Male, Psychotropic Drugs, Troubles bipolaires, Psychopharmacology, Bipolar disorder, Recommandations, Middle Aged, Guidelines, Long-Term Care, Risk Assessment, Pharmacotherapy, Psychopharmacologie, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Acute Disease, Chronic Disease, Humans, Drug Therapy, Combination, Female, France, Biological Psychiatry, Societies, Medical
Abstract

International audience; As part of a process to improve the quality of care, the French Society for Biological Psychiatry and Neuropsychopharmacology developed in 2010 formal consensus guidelines for the treatment of bipolar disorder. The evolution of therapeutic options available in France for the treatment of bipolar disorder has justified the update of this guideline. The purpose of this work was to provide an updated and ergonomic document to promote its use by clinicians. This update focuses on two of the six thematic previously published (acute treatment and long-term treatment). Aspects of the treatment of bipolar patients sparking debate and questions of clinicians (use of antidepressant, place of the bitherapy, interest of long-acting antipsychotics…) were also covered. Finally, we proposed graded recommendations taking into account specifically the risk-benefit balance of each molecule.

Published
2015

58. PMH35 – Cost-Effectiveness of Paliperidone Palmitate Versus other Antipsychotics for the Treatment of Schizophrenia in France

Author

Doutriaux, A., Cognet, M., Druais, S., Lançon, C., Samalin, L., Levy, P., Godet, A., Guillon, P., Laboratoire d'Economie de Dauphine (LEDa), Université Paris Dauphine-PSL, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL), and Laboratoire d'Economie et de Gestion des Organisations de Santé (Legos)

Subjects
Medical care costs, JEL: I - Health, Education, and Welfare/I.I1 - Health/I.I1.I11 - Analysis of Health Care Markets, [QFIN]Quantitative Finance [q-fin], cost effectiveness analysis, economic cost, health care economics and organizations
Abstract

International audience; To estimate the cost-effectiveness of paliperidone palmitate (PLAI), a once-monthly long-acting injectable (LAI) atypical antipsychotic, compared to the most common antipsychotic strategies in France.

Published
2014

65. Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection

Author

Llorca, Pierre-Michel, Samalin,L, Charpeaud, and Lorabi

Subjects
Patient Preference and Adherence
Abstract

L Samalin, T Charpeaud, O Lorabi, PM LlorcaCentre Hospitalier Universitaire, Clermont-Ferrand, FranceAbstract: In the last few years, oral second-generation antipsychotics have demonstrated mood-stabilizing properties and are now widely used in the treatment of bipolar disorder. Unfortunately, treatment of this chronic and complex illness is hampered with poor adherence on the part of patients. Long-acting injectable formulations of second-generation antipsychotics could combine the effect of oral second-generation antipsychotics in patients with bipolar disorder and the benefits of depot formulation with the assurance of steady medication delivery and thereby improve adherence. In this context, the efficacy and tolerance of risperidone long-acting injection (RLAI) for maintenance treatment in patients with bipolar disorder is assessed. The relevant studies found RLAI to be effective in preventive treatment of manic but not depressive recurrences in bipolar patients, with good tolerance. RLAI appeared to be particularly suitable for patients with known poor adherence to treatment or severe bipolar disorder (such as patients who relapse frequently). Lastly, if RLAI, unlike the first-generation antipsychotics, does not induce depressive symptoms, the different studies do not enable us to consider its use in monotherapy in the preventive treatment of patients with depressive polarity. Long-acting second-generation antipsychotics in bipolar patients are therefore associated with long-term benefits, but their use in clinical practice needs to be improved.Keywords: bipolar disorder, depot antipsychotics, long-acting risperidone injection, ­maintenance treatment, compliance

Published
2010

78. Residual symptoms in bipolar disorder

Author

Yon, L, primary, Samalin, L, additional, Giordana, B, additional, Milhet, V, additional, Marty, L, additional, El Hage, W, additional, Courtet, P, additional, Bellivier, F, additional, and Llorca, PM, additional

Published
2012
Full Text
View/download PDF

85. L’initiation thérapeutique dans les épisodes psychotiques et maniaques : recueil des attitudes françaises par Focus Group

Author

Benoit, M., primary, Bellivier, F., additional, Llorca, P.-M., additional, Millet, B., additional, Passamar, M., additional, Schwan, R., additional, Marty, L., additional, Cailhol, L., additional, Giordana, B., additional, Naudet, F., additional, Samalin, L., additional, Tadri, M., additional, Yon, L., additional, Hacques, E., additional, and Moreau-Mallet, V., additional

Published
2012
Full Text
View/download PDF

97. Adherence to guidelines by French psychiatrists in their real world of clinical practice.

Author

Samalin L, Guillaume S, Auclair C, and Llorca PM

Abstract

The treatment modalities of bipolar disorder and adherence to international guidelines recommendations in France were investigated. We conducted an observational survey among 210 French psychiatrists concerning their prescribing practice in bipolar disorder, and whether they use guidelines or not. Simple mania is mainly treated with valproate, whereas second-generation antipsychotics are preferred for delusional mania. Lithium is mostly used as second-line treatment by 'young psychiatrists.' Personal experience appears in the foreground (41% of psychiatrists) in the choice of therapy. Young psychiatrists refer more to guidelines (32% of responders) as compared with other psychiatrists. The main reason for the lack of use of guidelines is because they refer mostly to an Anglo-Saxon medical practice, which is considered different from the French practice. Guidelines for treatment of bipolar disorder are not frequently used. French psychiatrists' age and practice type are the most important variables correlated to the level of use of guidelines. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results